NDAVAGINALCREAM
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
3/8 — Basic
GYNE-LOTRIMIN 3 (clotrimazole) by Bayer is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and malassezia furfur . First approved in 1998.
Drug data last refreshed 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GYNE-LOTRIMIN 3 is a broad-spectrum antifungal cream containing clotrimazole, approved for vaginal administration to treat vulvovaginal candidiasis and other candida-related mycoses. It works by disrupting fungal cell membranes through inhibition of ergosterol synthesis, causing leakage of intracellular contents and cell death. The product is a topical formulation with minimal systemic absorption.
LOE Approaching
Product is in late lifecycle stage with declining market exclusivity; commercial teams are likely focused on defensive strategies and managed care negotiations rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and Malassezia furfur . The primary action of clotrimzole is against dividing and growing organisms. In vitro ,…
Worked on GYNE-LOTRIMIN 3 at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.